These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35569591)

  • 1. Management of juvenile-onset systemic sclerosis with systemic immunosuppressive therapies: An evidence-based review.
    Abduelmula A; Rankin BD; Luca NJ; Prajapati VH
    J Am Acad Dermatol; 2023 Jan; 88(1):234-236. PubMed ID: 35569591
    [No Abstract]   [Full Text] [Related]  

  • 2. New developments in juvenile systemic and localized scleroderma.
    Foeldvari I
    Rheum Dis Clin North Am; 2013 Nov; 39(4):905-20. PubMed ID: 24182860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and localized scleroderma in children: current and future treatment options.
    Rosenkranz ME; Agle LM; Efthimiou P; Lehman TJ
    Paediatr Drugs; 2006; 8(2):85-97. PubMed ID: 16608370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment in Juvenile Scleroderma.
    Zulian F; Tirelli F
    Curr Rheumatol Rep; 2020 Jun; 22(8):45. PubMed ID: 32591919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma in children.
    Zulian F
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):576-595. PubMed ID: 29773274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis and localized scleroderma in childhood.
    Zulian F
    Rheum Dis Clin North Am; 2008 Feb; 34(1):239-55; ix. PubMed ID: 18329543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis.
    Li SC
    Pediatr Clin North Am; 2018 Aug; 65(4):757-781. PubMed ID: 30031497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of morphea with systemic immunosuppressive therapies: An evidence-based review.
    Abduelmula A; Rankin BD; Riaz S; Ross N; Luca NJ; Prajapati VH
    J Am Acad Dermatol; 2023 Feb; 88(2):467-469. PubMed ID: 35716832
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there a therapeutic role for immunosuppression for gastrointestinal involvement in patients with systemic sclerosis?
    McMahan ZH; Hughes M
    Rheumatology (Oxford); 2024 Jul; 63(7):1766-1768. PubMed ID: 38109678
    [No Abstract]   [Full Text] [Related]  

  • 10. Scleroderma in children: an update.
    Zulian F; Cuffaro G; Sperotto F
    Curr Opin Rheumatol; 2013 Sep; 25(5):643-50. PubMed ID: 23912318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma.
    Torok KS
    Rheum Dis Clin North Am; 2021 Nov; 47(4):757-780. PubMed ID: 34635303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.
    Fett N
    Clin Dermatol; 2013; 31(4):432-437. PubMed ID: 23806160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic sclerosis (scleroderma) without scleroderma].
    Nadashkevych ON
    Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of scleroderma and dermatomyositis in childhood].
    Ansell BM
    Clin Ter; 1978 Jan; 84(2):123-31. PubMed ID: 648095
    [No Abstract]   [Full Text] [Related]  

  • 15. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.
    Hoa S; Bernatsky S; Baron M; Proudman S; Stevens W; Sahhar J; Wang M; Steele RJ; ; ; Nikpour M; Hudson M
    Chest; 2021 Dec; 160(6):2158-2162. PubMed ID: 34153341
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.
    Ingegnoli F; Boracchi P; Gualtierotti R; Smith V; Cutolo M; Foeldvari I;
    Microvasc Res; 2015 Nov; 102():19-24. PubMed ID: 26254260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Other rheumatic diseases in adolescence. Dermatomyositis, scleroderma, overlap syndromes, systemic vasculitis, and panniculitis.
    Hom C; Ilowite NT
    Adolesc Med; 1998 Feb; 9(1):69-83, vi. PubMed ID: 10961253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus-based recommendations for the management of juvenile systemic sclerosis.
    Foeldvari I; Culpo R; Sperotto F; Anton J; Avcin T; Baildam E; Boros C; Chaitow J; Constantin T; Kasapcopur O; Knupp Feitosa de Oliveira S; Pilkington C; Toplak N; van Royen A; Saad Magalhaes C; Vastert SJ; Wulffraat N; Zulian F
    Rheumatology (Oxford); 2021 Apr; 60(4):1651-1658. PubMed ID: 33147624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points.
    Foeldvari I; Torok KS
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101688. PubMed ID: 33896752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.